September 2, 2024
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
- /
- /
- /
- /
September 2, 2024 • In the HERCULES study, tolebrutinib met the primary endpoint in delaying time to onset of confirmed…